MILWAUKEE, April 2, 2024 /PRNewswire/ — Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate statements Morphic may have made regarding its business operations and prospects.
Click here to learn more about the investigation: https://www.ademilaw.com/case/morphic-holding-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Morphic’s representations regarding its Phase 2a trial for MORF-057 proposed to be used in the treatment of severely active ulcerative colitis. In September 2023, Morphic announced that endoscopic improvement was achieved in 25.7% of patients in the trial at week 12, which was a lower rate than on other ulcerative colitis trials from competitors. These other trials typically found that the rate of endoscopic improvement was higher than the rate of clinical remission.
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, https://www.ademilaw.com/case/morphic-holding-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
SOURCE Ademi LLP
